Latest news with #NYSEAMERICAN
Yahoo
4 days ago
- Business
- Yahoo
Energy Fuels (UUUU) is Among the Energy Stocks that Gained the Most This Week
The share price of Energy Fuels Inc. (NYSEAMERICAN:UUUU) surged by 10.93% between May 29 and June 5, 2025, putting it among the Energy Stocks that Gained the Most This Week. Let's shed some light on the development. Miners at work in a mine, searching for Uranium and Vanadium. Energy Fuels Inc. (NYSEAMERICAN:UUUU) is a leading US-based critical minerals company, focused on uranium, rare earth elements, heavy mineral sands, vanadium, and medical isotopes. Investors reacted positively this week after Energy Fuels Inc. (NYSEAMERICAN:UUUU) disclosed that it had achieved record monthly uranium production at its Pinyon Plain mine in Arizona, with May's output reaching nearly 260,000 pounds of U3O8. Moreover, the company filed an updated technical report on its Bullfrog project in Utah, significantly increasing previously reported in-ground uranium resources. These developments are especially significant given a recent executive order by President Trump to reinvigorate the American nuclear sector and quadruple the country's nuclear energy capacity. The order also calls for an increase in domestic mining and enrichment of uranium, and a reduction in reliance on imports from Russia and China. While we acknowledge the potential of UUUU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Cheap Energy Stocks to Buy Now and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Espey Declares Regular Quarterly Dividend of $0.25 Per Share
SARATOGA SPRINGS, N.Y., June 05, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Espey Mfg. & Electronics Corp. (NYSE AMERICAN: ESP) has declared a regular quarterly dividend of $0.25 per share. The dividend will be payable on June 23, 2025 to all shareholders of record on June 16, 2025. Espey's primary business is the development, design, and production of specialized military and industrial power supplies/transformers. The Company can be found on the Internet at For further information, contact Ms. Kaitlyn O'Neil at invest@ Certain statements in this press release are "forward-looking statements" and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company's current expectations or beliefs concerning future events. The matters covered by these statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. The Company wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
Espey Declares Regular Quarterly Dividend of $0.25 Per Share
SARATOGA SPRINGS, N.Y., June 05, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Espey Mfg. & Electronics Corp. (NYSE AMERICAN: ESP) has declared a regular quarterly dividend of $0.25 per share. The dividend will be payable on June 23, 2025 to all shareholders of record on June 16, 2025. Espey's primary business is the development, design, and production of specialized military and industrial power supplies/transformers. The Company can be found on the Internet at For further information, contact Ms. Kaitlyn O'Neil at invest@ Certain statements in this press release are "forward-looking statements" and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company's current expectations or beliefs concerning future events. The matters covered by these statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. The Company wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date in to access your portfolio
Yahoo
6 days ago
- Business
- Yahoo
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
HENDERSON, Nevada, June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems. Dr Sato, a key opinion leader is Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of the largest referral hospitals in Japan. AMAMS 2025 is taking place in Thailand. Commenting on the results Dr Sato said: "The Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool, particularly for differentiating between benign and malignant conditions such as Canine Chronic Enteropathy and Gastrointestinal Lymphoma." Kiyotaka Fujiwara, Chief Operating Officer at Fujifilm Vet Systems, added: "We are delighted that leading veterinarian Dr Sato has adopted the Nu.Q® Vet Cancer Test in Japan, and not only researching, but publishing specific use cases. We believe this will further raise the awareness of the test and drive wider adoption." The presentations: Title: "Diagnostic Utility of Plasma Nucleosome Concentration in Differentiating Canine Chronic Enteropathy from Gastrointestinal Lymphoma" Presenter: Kentaro NabeshimaDate and Time: Thursday, June 5, 2025, 1:40PM – 1:50PM (ICT)Venue: Room 108Key Conclusion: Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool for distinguishing CE from GIL, with particularly high levels observed in medium-to-large cell "Evaluation of Plasma Nucleosome Concentrations as a Biomarker for Canine Nasal Tumors"Presenter: Chihoko TakahashiDate and Time: Thursday, June 5, 2025, 3:30PM – 3:40PM (ICT)Venue: Room 108 About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only. Media Enquiries:Louise Batchelor, Volition, mediarelations@ +44 (0)7557 774620 Investor Relations:Jeremy Feffer, LifeSci Advisors, jfeffer@ +1-212-915-2568 Safe Harbor Statement Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America. View original content: SOURCE VolitionRx Limited Sign in to access your portfolio
Business Wire
03-06-2025
- Business
- Business Wire
flyExclusive to Participate in a Fireside Chat at Jefferies' 2025 Business Aviation Summit
KINSTON, N.C.--(BUSINESS WIRE)--flyExclusive, Inc. (NYSEAMERICAN: FLYX) ('flyExclusive' or the 'Company'), a publicly-traded provider of premium private jet charter experiences, today announced that Jim Segrave, Founder and Chief Executive Officer, will participate in a virtual fireside chat at Jefferies' 2025 Business Aviation Summit on June 5, 2025. The presentation will begin at approximately 12:40 p.m. ET and will be available for registered conference attendees. Registered conference attendees can also view a replay of the presentation for 30 days after the event. About flyExclusive flyExclusive is a vertically integrated, FAA-certificated air carrier providing private jet experiences by offering customers a choice of on-demand charter, Jet Club, and fractional ownership services to destinations across the globe. flyExclusive has one of the world's largest fleets of Cessna Citation aircraft, and it operates a combined total of approximately 100 jets, ranging from light to large cabin sizes. The company manages all aspects of the customer experience, ensuring that every flight is on a modern, comfortable, and safe aircraft. flyExclusive's in-house repair station, aircraft paint, cabin interior renovation, and avionics installation capabilities, are all provided from its campus headquarters in Kinston, North Carolina. To learn more, visit
